STOCK TITAN

Guardant Health’s Terilyn J. Monroe sells 3,842 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Guardant Health, Inc. Chief People Officer Terilyn J. Monroe reported direct sales of 3,842 common shares on November 18, 2026 under a Rule 10b5-1 trading plan. The first four reported sale blocks were 500 shares at a weighted-average price of $140.6400 per share, 1,200 at $141.7888, 1,338 at $142.8291, and 704 at $143.6356. The fifth block was 100 shares at $144.5800 per share.

Insider Monroe Terilyn J.
Role Chief People Officer
Sold 3,842 shs ($547K)
Share of Position Sold 15.4%
Type Security Shares Price Value
Sale Common Stock F1 500 $140.64 $70K
Sale Common Stock F2 1,200 $141.7888 $170K
Sale Common Stock F3 1,338 $142.8291 $191K
Sale Common Stock F4 704 $143.6356 $101K
Sale Common Stock 100 $144.58 $14K
Holdings After Transaction: Common Stock — 21,058 shares (Direct)
Holdings Before and After: Common Stock, 24,900 to 21,058 shares (Direct)
Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (4)
  1. F1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.335 to $140.890. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  2. F2. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.385 to $142.310. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F3. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $142.41 to $143.19. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. F4. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $143.420 to $144.115. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
First sale block 500 shares at $140.6400 per share Weighted-average price; November 18, 2026
Second sale block 1,200 shares at $141.7888 per share Weighted-average price; November 18, 2026
Third sale block 1,338 shares at $142.8291 per share Weighted-average price; November 18, 2026
Fourth sale block 704 shares at $143.6356 per share Weighted-average price; November 18, 2026
Fifth sale block 100 shares at $144.5800 per share November 18, 2026
Rule 10b5-1 regulatory
"reported transactions under a Rule 10b5-1 plan"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
weighted average sales price financial
"Represents the weighted average sales price per share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GH shares did Guardant Health's Chief People Officer sell?

Terilyn J. Monroe reported sales of 3,842 common shares on November 18, 2026, under a Rule 10b5-1 plan.

What prices were reported for Terilyn J. Monroe's GH share sales?

The first four blocks had weighted-average prices of $140.6400, $141.7888, $142.8291 and $143.6356 per share; the fifth block was 100 shares at $144.5800 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Monroe Terilyn J.

(Last)(First)(Middle)
3100 HANOVER STREET

(Street)
PALO ALTO CALIFORNIA 94304

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief People Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/18/2026S500D$140.64(1)24,400D
Common Stock11/18/2026S1,200D$141.7888(2)23,200D
Common Stock11/18/2026S1,338D$142.8291(3)21,862D
Common Stock11/18/2026S704D$143.6356(4)21,158D
Common Stock11/18/2026S100D$144.5821,058D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.335 to $140.890. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
2. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.385 to $142.310. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
3. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $142.41 to $143.19. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
4. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $143.420 to $144.115. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
Remarks:
/s/ John G. Saia, as attorney-in-fact for Terilyn J. Monroe11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading